Option and License AgreementOption and License Agreement • February 5th, 2013 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • London
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis Merck Serono granted option for exclusive license from Opexa to develop and commercialize...Opexa Therapeutics, Inc. • February 5th, 2013 • Pharmaceutical preparations
THE WOODLANDS, Texas--(BUSINESS WIRE)--February 1, 2013--Opexa Therapeutics, Inc. (NASDAQ: OPXA) today announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna™ (imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Tcelna (imilecleucel-T) is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS). Potential payments to Opexa from the option and license agreement could total $225 million based upon the successful development and commercialization of Tcelna for MS.
